Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients Undergoing Laparoscopic Cancer Surgeries: A Randomized Controlled Trial
Overview
- Phase
- Phase 2
- Intervention
- Dexmedetomidine Injection [Precedex]
- Conditions
- Obesity; Drug
- Sponsor
- National Cancer Institute, Egypt
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Oxygenation by the end study drug infusion
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
• The objective of this study is to evaluate the effect of different doses of dexmedetomidine infusion intraoperative on lung mechanics and oxygenation regarding PaO2/Fraction of inspired oxygen), Intraoperative oxygenation, lung compliance (static and dynamic), dead space, and PaCO2,heart rate, mean arterial blood pressure in obese patients undergoing laparoscopic cancer surgeries
Detailed Description
Dexmedetomidine is a selective agonist of α2receptorswhose tendency to α2 receptors is eight times more than that of clonidine. It also has powerful sedative, analgesic, anti-inflammatory, and organ protective properties. dexmedetomidine has favorable respiratory effects in humans. The effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease. Dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (COPD) patients undergoing lung cancer surgery. Morbidly obese patients are characterized by the high prevalence of restrictive lung disease.The study include 2 equal groups, each group is 35 patients: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery and Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
Investigators
Mohammed Abdelfattah Abdelwadod
Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine
National Cancer Institute, Egypt
Eligibility Criteria
Inclusion Criteria
- •Age 18-60years
- •Obese patients BMI\>25 Kg/meter square
- •Patients undergoing laparoscopic cancer surgery.
Exclusion Criteria
- •Heart failure
- •Arrhythmias
- •Severe liver or kidney impairment
- •Patients with forced expiratory volume in 1 sec (FEV1)/FVC \< 70%
- •Heart block
Arms & Interventions
( Group A)
: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
Intervention: Dexmedetomidine Injection [Precedex]
(Group B)
Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
Intervention: Dexmedetomidine Injection [Precedex]
Outcomes
Primary Outcomes
Oxygenation by the end study drug infusion
Time Frame: baseline and end of surgery
PaO2/Fraction of inspired oxygen
Secondary Outcomes
- lung compliance(baseline and end of surgery)